Home LiteratureArticle Details
PMID: 16052217 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.

British journal of cancer ·Vol. 93 ·No. 3 ·2005-08-08 ·Pages 302-9

Mellor HR, Ferguson DJ, Callaghan R

Abstract

The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon adenocarcinoma (DLD-1) cells to mimic the microenvironment of quiescent microregions of solid tumours. The quiescent tumour spheroids (TS(Q)) showed decreased expression of the proliferation marker Ki-67 and increased expression of the quiescence marker p27(kip1) compared to proliferating spheroids (TS(P)). The quiescent status of the TS(Q) was confirmed by long-term growth assessment. The quiescence was completely reversible demonstrating that the TS(Q) retained the ability to proliferate and morphological assessment by light microscopy confirmed the absence of significant apoptosis. When the efficacy of widely used chemotherapeutic drugs was determined, vinblastine, doxorubicin, cisplatin and 5-fluorouracil (5-FU) all produced significant cell death in the TS(P). However, while still effective, the potencies of doxorubicin and cisplatin were significantly reduced in TS(Q). In contrast, 5-FU and vinblastine did not produce cell death in the TS(Q). In summary, TS(Q) show considerable resistance to a panel of established chemotherapeutic agents and represent a useful model for evaluating the efficacy of drugs and other cancer therapies in quiescent tumours.

MeSH Terms
Adenocarcinoma/drug therapy Antineoplastic Agents/pharmacology Cell Line, Tumor Cell Proliferation/drug effects Drug Resistance, Neoplasm/physiology Humans Models, Biological Spheroids, Cellular/drug effects
Chemicals
Antineoplastic Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Mellor H R
Oxford Drug Resistance Group, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK.
Ferguson D J P
Callaghan R
References (38)
38 references, click to expand
  1. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.
    Cell. 1994 Jul 15;78(1):67-74 PMID: 8033213
  2. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer.
    J Urol. 1989 Nov;142(5):1342-6 PMID: 2478729
  3. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
    Cancer Res. 1998 Apr 1;58(7):1408-16 PMID: 9537241
  4. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture.
    Growth. 1970 Sep;34(3):271-82 PMID: 5471822
  5. Proliferation-dependent cytotoxicity of anticancer agents: a review.
    Cancer Res. 1975 Oct;35(10):2619-30 PMID: 1098765
  6. Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours.
    Br J Cancer. 1997;75(2):196-201 PMID: 9010026
  7. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.
    Nat Med. 1996 Nov;2(11):1204-10 PMID: 8898746
  8. Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models.
    Biochem Pharmacol. 2004 Jan 1;67(1):17-30 PMID: 14667925
  9. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy.
    Ann N Y Acad Sci. 1993 Nov 30;698:193-203 PMID: 8279757
  10. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.
    Eur J Cancer. 2004 Jan;40(2):205-11 PMID: 14728934
  11. Microtubules as a target for anticancer drugs.
    Nat Rev Cancer. 2004 Apr;4(4):253-65 PMID: 15057285
  12. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Cancer Res. 2003 Aug 1;63(15):4322-6 PMID: 12907598
  13. The Ki-67 protein: from the known and the unknown.
    J Cell Physiol. 2000 Mar;182(3):311-22 PMID: 10653597
  14. Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments.
    Radiat Med. 1999 Jul-Aug;17(4):259-64 PMID: 10510897
  15. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
    Biochem Pharmacol. 1999 Apr 1;57(7):727-41 PMID: 10075079
  16. Growth of multicell spheroids in tissue culture as a model of nodular carcinomas.
    J Natl Cancer Inst. 1971 Jan;46(1):113-20 PMID: 5101993
  17. Mitotic index and ki-67 nuclear antigen labeling index as predictors of chemotherapy response in uterine cervical carcinoma.
    Gynecol Oncol. 2001 Dec;83(3):555-9 PMID: 11733971
  18. Cisplatin and DNA repair in cancer chemotherapy.
    Trends Biochem Sci. 1995 Oct;20(10):435-9 PMID: 8533159
  19. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1.
    Cancer Res. 2003 Apr 1;63(7):1706-11 PMID: 12670925
  20. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.
    Pharmacol Rev. 2004 Jun;56(2):185-229 PMID: 15169927
  21. The tumor microenvironment: a double-edged sword.
    Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):697-9 PMID: 9845079
  22. The relevance of drug sequence in combination chemotherapy.
    Drug Resist Updat. 2000 Dec;3(6):335-356 PMID: 11498402
  23. Cell-cycle dependence of foamy virus vectors.
    J Gen Virol. 2004 Oct;85(Pt 10):2925-30 PMID: 15448354
  24. Multicellular resistance: a paradigm for clinical resistance?
    Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207 PMID: 11033306
  25. Hypoxia inhibits G1/S transition through regulation of p27 expression.
    J Biol Chem. 2001 Mar 16;276(11):7919-26 PMID: 11112789
  26. Differential responses of proliferating versus quiescent cells to adriamycin.
    Exp Cell Res. 1999 Jul 10;250(1):131-41 PMID: 10388527
  27. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
    Br J Cancer. 1995 May;71(5):1029-32 PMID: 7734295
  28. A new screening system for proliferation-independent anti-cancer agents.
    Cancer Lett. 2004 Jul 8;210(1):119-24 PMID: 15172129
  29. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling.
    Biochem Pharmacol. 2003 Oct 15;66(8):1547-54 PMID: 14555233
  30. Multicellular spheroids as an in vitro tumor model.
    Cancer Lett. 1998 Sep 11;131(1):29-34 PMID: 9839617
  31. The problem of the quiescent cancer cell.
    Adv Enzyme Regul. 1989;29:27-46 PMID: 2633613
  32. Growth-related glycogen levels of human intestine carcinoma cell lines grown in vitro and in vivo in nude mice.
    J Natl Cancer Inst. 1980 Nov;65(5):885-9 PMID: 6933258
  33. p27 as a target for cancer therapeutics.
    Cancer Cell. 2003 Feb;3(2):111-5 PMID: 12620406
  34. 5-fluorouracil: mechanisms of action and clinical strategies.
    Nat Rev Cancer. 2003 May;3(5):330-8 PMID: 12724731
  35. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
    Oncogene. 2003 Oct 20;22(47):7265-79 PMID: 14576837
  36. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
    Am J Pathol. 1999 Feb;154(2):313-23 PMID: 10027389
  37. The Ki-67 protein: fascinating forms and an unknown function.
    Exp Cell Res. 2000 Jun 15;257(2):231-7 PMID: 10837136
  38. Implication of cell kinetic changes during the progression of human prostatic cancer.
    Clin Cancer Res. 1995 May;1(5):473-80 PMID: 9816006
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
Published
2005-08-08
Pages
302-9
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2361565
Subset
IM
Grants
Wellcome Trust · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]